division of pharmaceutical analysis l.
Skip this Video
Loading SlideShow in 5 Seconds..
Division of Pharmaceutical Analysis PowerPoint Presentation
Download Presentation
Division of Pharmaceutical Analysis

Loading in 2 Seconds...

play fullscreen
1 / 16

Division of Pharmaceutical Analysis - PowerPoint PPT Presentation

  • Uploaded on

Division of Pharmaceutical Analysis. Lucinda F. Buhse, Ph.D., Director. Research in support of the Critical Path Dimensions Ensuring Safety Demonstrating Medical Utility Industrialization Process. Division of Pharmaceutical Analysis Critical Path Initiatives.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

Division of Pharmaceutical Analysis

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
division of pharmaceutical analysis

Division of Pharmaceutical Analysis

Lucinda F. Buhse, Ph.D., Director

Research in support of the Critical Path Dimensions

Ensuring Safety

Demonstrating Medical Utility

Industrialization Process

division of pharmaceutical analysis critical path initiatives
Division of Pharmaceutical AnalysisCritical Path Initiatives
  • Characterize Novel Dosage Forms/ Complex Drug Substances
  • Measurement and ID of Micro and Nanoparticles
  • Establish Appropriate Surrogate Measurements Techniques
  • Drug Authenticity and Anti-counterfeiting Techniques
  • Process Analytical Technologies for Manufacturing
  • Computational Chemistry (Chemometrics)
characterization of novel dosage forms complex drug substances
Characterization of Novel Dosage Forms/ Complex Drug Substances


  • Liposomes –characterization after chemical and physical changes
  • Transdermals – physical characterization of adhesive strength
  • Conjugated Estrogens – improvement of LCMS comparison method
  • Protein Products -Detection of Aggregation and Degradation

Regulatory Accomplishments:

  • Input into Conjugated Estrogens Guidance
monitoring liposomal drug products ldps under manufacturing stress conditions

Monitoring Liposomal Drug Products (LDPs) Under Manufacturing Stress Conditions

LDPs (PEGylated Doxil ®, Conventional DaunoXome®)

Stress Conditions



Acid and Base




Analytical methods for Monitoring quality

Drug Substance (HPLC-UV)

Encapsulation Efficiency (fluorescence)

Lipid Composition (HPLC-ELS)

Particle Size

Zeta Potential

transdermal drug delivery systems adhesive strength

Several sizes of patches, types of drug delivery, application periods, and shapes.

Transdermal Drug Delivery Systems: Adhesive Strength

Example of drug-in-adhesive

Example of reservoir

Test method development variables and constants:

Test panel Rolls Rolling time Test panel cleaning

Angle of pull Pull speed Dwell time Environment

measurement and id of micro and nanoparticles
Measurement and ID of Micro and Nanoparticles


  • Sunscreens – evaluation of particle size in the formulation
  • Nasal Sprays
    • evaluation of Raman Microimaging for particle sizing of active pharmaceutical ingredient
    • evaluation of Andersen Cascade Impactor configuration for use in assessing the distribution of fine particles

Regulatory Accomplishments:

  • Input into Nasal Spray BA/BE Guidance
  • Development of compendial method for cyclosporine particle size
establishment of appropriate surrogate measurement techniques
Establishment of Appropriate Surrogate Measurement Techniques


  • Mefloquine HCl – evaluation of polymorphs of API with respect to BA of finished dosage form
  • Megestrol Acetate – evaluation of dissolution media to detect BE/BA differences
  • Evaluation of variability in Dissolution testing – search for an alternative technique to establish BE/BA

Regulatory Accomplishments:

  • Input into resolution of prophylaxis failure of military use product
  • Input into resolution of generic manufacturer equivalency challenge
dissolution less variability is needed
Dissolution: Less variability is needed
  • The current USP 10-mg Prednisone Calibrator Tablets exhibit slower dissolution over time
  • Acceptance limits are so large, that improper mechanical calibration may not be detected
  • Differences in product testing can often be traced to improper mechanical calibration and/or degassing

Drug Authenticity and Anti-counterfeiting



  • Assessment of technologies for detection of counterfeit (IRMS, NIR, TGA, Terahertz)

Regulatory Accomplishments:

  • Quality of foreign Active Pharmaceutical Ingredients program
  • Foreign Internet Sample Studies

IRMS- Isotope Ratio Mass Spectrometry

IRMS can provide the source of active pharmaceutical ingredients (APIs). In the bivariate isotope ratio graph shown, the typical clustering of the data is consistent with manufacturer-based isotopic provenance.

process analytical technologies for manufacturing
Process Analytical Technologies for Manufacturing


  • Assessment of technologies for PAT (Terahertz, NIR)
  • Effect of coating composition and thickness on PAT measurements
  • Effect of excipient and excipient/drug interaction
terahertz spectrometry

Terahertz Absorption Spectra

Partial Least Squares Fit

THz Predicted Content (mg)


Content (mg) by NIR PLS Calibration from HPLC

Energy (5 - 45cm-1)

  • Non-Destructive and Penetrating
  • Imaging of Biological Tissue
  • On-Line or At-Line Quality Control including whole tablet imaging

Terahertz Spectrometry

Acetaminophen tablet content: 65 – 135 mg scanned by NIR and Terahertz Absorbance.

computational chemistry chemometrics
Computational Chemistry (Chemometrics)


  • Understanding chemometric software packages
  • Understanding limitations and benefits of multivariate techniques
critical path chemometrics

Uncoated Acetaminophen tablets in 9 dosage levels 65 – 135mg.

Critical Path - Chemometrics

Tablet Reflectance – full range

Tablet Transmittance – limited spectral range

Data Range: 4000 – 10000cm-1

Data Range: 8600 – 10000cm-1



Near Infrared Reflectance and Transmittance of formulated tablets

Multivariate models in PAT – Partial Least Squares (PLS) analysis

Energy (cm-1)

Energy (cm-1)

PLS – Mean Centered, 2nd Derivative, 3 Factors

PLS – Mean Centered, Direct Spectra, 3 Factors

Calculated Content

Calculated Content

Content Measured by HPLC

Content Measured by HPLC